Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
Pharming said the U.S. FDA accepted its resubmitted supplemental NDA for Joenja (leniolisib) to treat children ages 4–11 with APDS. After a Jan. 30, 2026 CRL and a March 26 Type A meeting, the sNDA seeks approval for 40 mg and 50 mg twice daily for patients ≥27 kg, with FDA requesting additional batch-testing analytical data. The PDUFA target action date is Oct. 24, 2026. A separate sNDA for lower-weight patients is planned for the second half of 2026.
How this was made
The 30-second read
Why it matters
FDA acceptance is a procedural but meaningful step that keeps the pediatric APDS expansion on track toward a dated FDA decision window (PDUFA Oct 24, 2026). Positive Phase III open-label single-arm data are cited, with mild-to-moderate AEs and no drug-related serious AEs reported over 12 weeks.
Market read
Traders may reprice probability-weighted approval odds and timing for Joenja’s pediatric label expansion, with the next major decision catalyst tied to the PDUFA date.
What to watch
The article notes additional analytical batch-testing data and a separate lower-dose sNDA planned for later in 2026—commercial impact may depend on final dosing/label breadth.
Background
Pharming previously received a Complete Response Letter for the pediatric sNDA (Jan 30, 2026) and held a Type A meeting with FDA (Mar 26, 2026) before resubmitting with additional analytical batch-testing data.
Ticker impact
FDA accepted Pharming’s sNDA resubmission for Joenja (leniolisib) in children 4–11 with APDS, setting a PDUFA action date of Oct 24, 2026.
Likely positive near-term bias as traders price higher probability of approval; upside capped by remaining FDA review/labeling details.
Acceptance of a resubmitted sNDA after a prior CRL is a concrete regulatory milestone, and the article provides the specific PDUFA target date and dosing scope.
Market effects
Supports sentiment for targeted immunology/PI3Kδ inhibitor franchises and rare-disease label expansions following prior CRLs.
Primarily U.S. regulatory catalyst with potential spillover into European rare-disease investor sentiment.
Could strengthen global commercial expectations for leniolisib if U.S. pediatric approval follows.
Counterpoint
Acceptance does not equal approval; the prior CRL implies unresolved issues could still lead to another delay or narrower label.
Key entities
- companyPharming Group N.V.
Subject of the FDA acceptance announcement for Joenja (leniolisib) pediatric sNDA resubmission.
- drugJoenja (leniolisib)
Oral PI3Kδ inhibitor being evaluated for children aged 4–11 with APDS.
- regulatorFDA
Accepted the resubmitted sNDA and set a PDUFA target action date of Oct 24, 2026.
